Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin Irritation Potential of FMX-101 in Healthy Volunteers
NCT04064125Phase 1Completed
- Sponsor
- Vyne Therapeutics
- Start
- Sep 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of minocycline in acne vulgaris (4 arms), sponsored by Vyne Therapeutics. Primary endpoint: Mean Cumulative Irritation Score at 3 weeks. Started Sep 2016; status: completed.
02
Drugs
minocycline
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT04064125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04064125.